Influence of genetic variants of opioid-related genes on opioid-induced adverse effects in patients with lung cancer: A STROBE-compliant observational study.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
05 11 2021
05 11 2021
Historique:
received:
26
05
2021
accepted:
02
10
2021
entrez:
6
12
2021
pubmed:
7
12
2021
medline:
16
2
2022
Statut:
ppublish
Résumé
Despite the dramatic advancement of cancer chemotherapy and immunotherapy, the insufficient progress has been made in basic or translational research on personalization of opioid therapy. Predicting the effectiveness of opioid analgesic therapy and the risk of adverse effects prior to therapy are expected to enable safer and more appropriate opioid therapy for cancer patients. In this study, we compared the incidence of opioid-induced adverse effects between patients with different variants of the genes related to responsiveness to opioid analgesics.Participants were 88 patients with lung cancer who provided general consent for exome sequencing and were treated with morphine or oxycodone at Shizuoka Cancer Center Hospital between April 2014 and August 2018. Incidence rates for 6 adverse effects of opioid therapy (somnolence, nausea, constipation, delirium, urinary retention, and pruritus) were determined and the influence of single nucleotide polymorphisms in coding regions of the opioid μ receptor 1 (OPRM1) (rs1799971), opioid δ receptor 1 (rs2234918), opioid κ receptor 1 (rs1051660), catechol-O-methyltransferase (COMT) (rs4680), dopamine receptor D2 (rs6275), adenosine triphosphate binding cassette B1 (rs1045642), G-protein regulated inward rectifier potassium channel 2 (rs2070995), and fatty acid amide hydrolase (rs324420) genes on those adverse effects were analyzed.Analysis of OPRM1 gene variant status (Asn133Asp A > G) showed that G/G homozygotes were at significantly lower risk of somnolence compared with A allele carriers (0% vs 28.4%; Fisher exact test, P = .005; OR, 0; 95% CI, 0-0.6), and analysis of COMT gene variant status (Val158Met, G > A) showed that G/G homozygotes were at significantly higher risk of somnolence compared with A allele carriers (35.0% vs 10.4%; Fisher exact test, P = .008; OR, 4.5; 95% CI, 1.4-18.1). No relationship between variant status and adverse effects was found for the other genes.These findings demonstrate that OPRM1 and COMT gene variants influence the risk of somnolence as an adverse effect of opioid analgesic therapy.
Identifiants
pubmed: 34871222
doi: 10.1097/MD.0000000000027565
pii: 00005792-202111050-00021
pmc: PMC8568420
doi:
Substances chimiques
Analgesics, Opioid
0
Receptors, Opioid, mu
0
Catechol O-Methyltransferase
EC 2.1.1.6
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e27565Subventions
Organisme : Japanese Society for Pharmaceutical Palliative Care and Sciences
ID : fiscal 2019
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Lyseng-Williamson K, Jarvis B. Imatinib. Drugs 2001;61:1765–74.
George S, Motzer RJ, Hammers HJ, et al. Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial. JAMA Oncol 2016;2:1179–86.
Zhong L, Li Y, Xiong L, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 2020;6:201.
Lu RM, Hwang YC, Liu IJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci 2020;27:01.
Fisher DJ, Villines D, Kim YO, Epstein JB, Wilkie DJ. Anxiety, depression, and pain: differences by primary cancer. Support Care Cancer 2010;18:801–10.
Japanese Society for Palliative Medicine. Clinical Guideline for Pharmacological Management of Cancer Pain (2020 Edition). Tokyo: Kanehara Shuppan; 2020.
Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008;11: (2 Suppl): S133–53.
Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004;28:497–504.
Soleimanpour H, Safari S, Shahsavari Nia K, Sanaie S, Alavian SM. Opioid drugs in patients with liver disease: a systematic review. Hapat Mon 2016;16:e32636.
Smith MT, Muralidharan A. Pharmacogenetics of pain and analgesia. Clin Genet 2012;82:321–30.
Pathan H, Williams J. Basic opioid pharmacology: an update. Br J Pain 2012;6:11–6.
Pergolizzi JV Jr, LeQuang JA, Berger GK, Raffa RB. The basic pharmacology of opioids informs the opioid discourse about misuse and abuse: a review. Pain Ther 2017;6:01–16.
Yamaguchi K, Urakami K, Ohshima K, et al. Implementation of individualized medicine for cancer patients by multiomics-based analyses–the Project HOPE. Biomed Res 2014;35:407–12.
Nagashima T, Yamaguchi K, Urakami K, Shimoda Y, et al. Japanese version of The Cancer Genome Atlas, JCGA, established using fresh frozen tumors obtained from 5143 cancer patients. Cancer Sci 2020;111:687–99.
Vainio A, Auvinen A. Prevalence of symptoms among patients with advanced cancer: an international collaborative study. J Pain Symptom Manage 1996;12:03–10.
Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587–93.
Ohnami S, Nagashima T, Urakami K, et al. Whole exome sequencing detects variants of genes that mediate response to anticancer drugs. J Toxicol Sci 2017;42:137–44.
Bastami S, Gupta A, Zackrisson A-L, Ahlner J, Osman A, Uppugunduri S. Influence of UGT2B7, OPRM1 and ABCB1 Gene Polymorphisms on postoperative morphine consumption. Basic Clin Pharmacol Toxicol 2014;115:423–31.
Olesen AE, Sato H, Nielsen LM, et al. The genetic influences on oxycodone response characteristics in human experimental pain. Fundam Clin Pharmacol 2015;29:417–25.
Ho KWD, Wallace MR, Staud R, Fillingim RB. OPRM1, OPRK1, and COMT genetic polymorphisms associated with opioid effects on experimental pain: a randomized, double-blind, placebo-controlled study. Pharmacogenomics J 2020;20:471–81.
Lucenteforte E, Vannacci A, Crescioli G, et al. Opioid response in pediatric cancer patients and the Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene: an Italian study on 87 cancer children and a systematic review. BMC Cancer 2019;19:113.
Ma L, Zhang X, Xiang Q, et al. Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis. Basic Clin Pharmacol Toxicol 2019;124:94–104.
Gong XD, Wang JY, Liu F, et al. Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain. Asian Pac J Cancer Prev 2013;14:2937–43.
Lötsch J, Prüss H, Veh RW, Doehring A. A KCNJ6 (Kir3.2, GIRK2) gene polymorphism modulates opioid effects on analgesia and addiction but not on pupil size. Pharmacogenet Genomics 2010;20:291–7.
Sadhasivam S, Zhang X, Chidambaran V, et al. Novel associations between FAAH genetic variants and postoperative central opioid related adverse effects. Pharmacogenomics J 2015;15:436–42.
De Gregori M, Diatchenko L, Ingelmo PM, et al. Human genetic variability contributes to postoperative morphine consumption. J Pain 2016;17:628–36.
Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008;83:559–66.
Peciña M, Love T, Stohler CS, Goldman D, Zubieta JK. Effects of the mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures. Neuropsychopharmacology 2015;40:957–65.
Mahmoud S, Thorsell A, Sommer WH, et al. Pharmacological consequence of the A118G mu opioid receptor polymorphism on morphine- and fentanyl-mediated modulation of Ca2+ channels in humanized mouse sensory neurons. Anesthesiology 2011;115:1054–62.
Margarit C, Ballester P, Inda MDM, et al. OPRM1 gene interaction with sleep in chronic pain patients treated with opioids. Pain Physician 2019;22:97–107.
Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996;6:243–50.
Bastos P, Gomes T, Ribeiro L. Catechol-O-methyltransferase (COMT): an update on its role in cancer, neurological and cardiovascular diseases. Rev Physiol Biochem Pharmacol 2017;173:01–39.
Coulbault L, Beaussier M, Verstuyft C, et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther 2006;79:316–24.